Cardiovascular events and their reduction with pravastatin in diabetic and glucose-intolerant myocardial infarction survivors with average cholesterol levels: subgroup analyses in the cholesterol and recurrent events (CARE) trial. The Care Investigators.
暂无分享,去创建一个
B. Davis | M. Pfeffer | E. Braunwald | B. Howard | F. Sacks | E. Braunwald | M. Mellies | R. Goldberg | W. Howard | T. Cole | L. Moyé | L. Moye
[1] Terje R Pedersen,et al. Cholesterol Lowering With Simvastatin Improves Prognosis of Diabetic Patients With Coronary Heart Disease: A subgroup analysis of the Scandinavian Simvastatin Survival Study (4S) , 1997, Diabetes Care.
[2] A. Dyer,et al. Diabetes, Asymptomatic Hyperglycemia, and 22-Year Mortality in Black and White Men: The Chicago Heart Association Detection Project in Industry Study , 1997, Diabetes Care.
[3] B. Davis,et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators. , 1996, The New England journal of medicine.
[4] R. Klein. Hyperglycemie and Microvascular and Macrovascular Disease in Diabetes , 1995, Diabetes Care.
[5] M. Pfeffer,et al. Rationale and design of a secondary prevention trial of lowering normal plasma cholesterol levels after acute myocardial infarction: the Cholesterol and Recurrent Events trial (CARE) , 1991, The American journal of cardiology.
[6] A. Folsom,et al. Trends in Prevalence of Diabetes Mellitus in Patients with Myocardial Infarction and Effect of Diabetes on Survival: The Minnesota Heart Survey , 1991, Diabetes Care.
[7] M. Harris. Epidemiological Correlates of NIDDM in Hispanics, Whites, and Blacks in the u.s. Population , 1991, Diabetes Care.
[8] V. Barriales,et al. [Heart disease and diabetes]. , 1991, Medicina clinica.
[9] E. Barrett-Connor,et al. Why is diabetes mellitus a stronger risk factor for fatal ischemic heart disease in women than in men? The Rancho Bernardo Study. , 1991, JAMA.
[10] L. Wilhelmsen,et al. A Cross‐sectional Analysis of Glucose Tolerance and Cardiovascular Disease in 67–year‐old Men , 1989, Diabetic Medicine.
[11] P. Bennett,et al. Prevalence of Diabetes and Impaired Glucose Tolerance and Plasma Glucose Levels in U.S. Population Aged 20–74 Yr , 1987, Diabetes.
[12] M. Laakso,et al. Diabetes and atherosclerosis: an epidemiologic view. , 1987, Diabetes/metabolism reviews.
[13] Y. Friedlander,et al. Analysis of risk factors in 532 survivors of first myocardial infarction hospitalized in Jerusalem. , 1986, Atherosclerosis.
[14] Kannel Wb,et al. Lipids, glucose intolerance and vascular disease: the Framingham Study. , 1985 .
[15] K. Anderson,et al. Lipids, glucose intolerance and vascular disease: the Framingham Study. , 1985, Monographs on atherosclerosis.
[16] P. Bennett,et al. The Role of Circulating Glucose and Triglyceride Concentrations and Their Interactions with Other “Risk Factors” as Determinants of Arterial Disease in Nine Diabetic Population Samples from the WHO Multinational Study , 1983, Diabetes Care.
[17] M. Shipley,et al. CORONARY-HEART-DISEASE RISK AND IMPAIRED GLUCOSE TOLERANCE The Whitehall Study , 1980, The Lancet.
[18] J. Kalbfleisch,et al. The Statistical Analysis of Failure Time Data , 1980 .
[19] D L McGee,et al. Diabetes and Glucose Tolerance as Risk Factors for Cardiovascular Disease: The Framingham Study , 1979, Diabetes Care.
[20] R. Levy,et al. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. , 1972, Clinical chemistry.
[21] D.,et al. Regression Models and Life-Tables , 2022 .